pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,016 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1788Endpoints1392Fierce Biotech712BioSpace702BioPharma Dive526raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12362Rare Disease3231Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines1802
  • Health AI progress limited by bad data, newsletter notes
    The latest AI Prognosis newsletter highlights that the quality of health data is a major obstacle for building useful AI tools in medicine. The author explains that many existing datasets contain…
    STAT · 6mo agoNeutral↗ source
  • HHS focuses on overmedication as cruise ship hantavirus outbreak prompts port change
    The Health and Human Services department announced new efforts to curb excessive prescribing, highlighting concerns about overmedication in the United States. At the same time, a cruise ship ancho…
    STAT · 6mo agoNeutral↗ source
← prev
page 115 of 121
next →
111
globenewswire health73
fda press59
Psychiatry & CNS1204
Ophthalmology1064
Pain778
Endocrinology & Metabolism777
Nephrology762
OpenAI’s health AI policy blueprint seen as reasonable yet self‑serving, experts say
OpenAI has expanded its health‑focused AI tools, rolling out ChatGPT Health for consumers, a hospital‑oriented ChatGPT for Healthcare, and a version for clinicians. Alongside the clinician chatbot,…
STAT · 6mo agoRegulatoryNegative↗ source
  • PeaceHealth abandons plan to outsource Oregon emergency doctors to ApolloMD after lawsuit and local opposition
    PeaceHealth, a nonprofit health system in Oregon, announced Wednesday that it will not move its emergency department staffing to the national physician staffing firm ApolloMD. The decision reverse…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Dementia care faces ambiguous loss, a unique grief that strains relationships
    Jason Karlawish, a professor of medicine and neurology at the University of Pennsylvania, wrote an opinion piece on the concept of ambiguous loss in dementia care. He reflects on a recent interview…
    STAT · 6mo agoNeutral↗ source
  • Dr. Glaucomflecken protests corporate staffing of PeaceHealth emergency department in Oregon
    Dr. Glaucomflecken, the online persona of physician Will Flanary, hosts the First Opinion Podcast where he blends humor with health‑care commentary. He has become a vocal critic of PeaceHealth’s p…
    STAT · 6mo agoNegative↗ source
  • Cytokinetics' Myqorzo meets primary goals in Phase 3 trial for non-obstructive hypertrophic cardiomyopathy
    Cytokinetics announced that its experimental therapy Myqorzo achieved its primary endpoints in a Phase 3 study of patients with non-obstructive hypertrophic cardiomyopathy (HCM). The trial showed…
    BioPharma Dive · 6mo agoPositive readoutPositive↗ source
  • Cytokinetics’ Myqorzo hits twin efficacy targets in genetic heart disease trial, while Viridian reports positive Phase 3 data for elegrobart
    Cytokinetics announced that its experimental heart‑failure drug Myqorzo achieved both primary efficacy endpoints in a study of patients with genetic cardiomyopathy, showing significant symptom impr…
    STAT · 6mo agoPositive readoutPositive↗ source
  • Vertex Q1 revenue slightly below forecasts as key drug sales miss estimates, but Alyftrek revenue surges
    Vertex Pharmaceuticals reported first‑quarter revenue of about $3 billion, falling just short of Wall Street expectations. The modest miss left the stock largely unchanged on the day of the release…
    BioPharma Dive · 6mo agoEarningsNeutral↗ source
  • Cytokinetics' Myqorzo hits both primary endpoints in Phase 3 trial for non-obstructive hypertrophic cardiomyopathy
    Cytokinetics announced that its drug Myqorzo achieved the dual efficacy targets in the Phase 3 ACACIA trial, which evaluated patients with non-obstructive hypertrophic cardiomyopathy (HCM), an inhe…
    STAT · 6mo agoPositive readoutPositive↗ source
  • Hantavirus outbreak on cruise ship highlights risks of U.S. exclusion from WHO
    Three passengers have died and seven others are ill after a suspected hantavirus infection was identified on a cruise vessel anchored off Cape Verde. The World Health Organization has taken the lea…
    STAT · 6mo agoRegulatoryNegative↗ source
  • J&J's IBD combo therapy misses statistical goal but will be tested in a focused patient subgroup
    Johnson & Johnson reported that its experimental combination of Tremfya and Simponi, called JNJ-4804, did not achieve a statistically significant improvement in a Phase 2b study of inflammatory bow…
    STAT · 6mo agoNegative readoutNegative↗ source
  • Viridian's elegrobart shows strong results in chronic thyroid eye disease trial, challenging Amgen's Tepezza
    Viridian Therapeutics announced that its injectable drug elegrobart met its primary goals in a late-stage study of patients with chronic thyroid eye disease. The trial reported response rates of 50…
    BioPharma Dive · 6mo agoPositive readoutPositive↗ source
  • Pharma's reputation among patient groups edges up to 57% but access and pricing concerns linger
    Patient groups surveyed by research firm PatientView gave drugmakers a 57% “good” or “excellent” reputation rating, the highest level since 2023. The survey covered more than 2,400 groups in 35 cou…
    STAT · 6mo agoNeutral↗ source
  • GOP Oversight Chair James Comer Targets AMA Billing Codes Over Fraud Concerns
    House Oversight Committee Chair James Comer, a Republican from Kentucky, is directing new scrutiny toward the American Medical Association's Current Procedural Terminology (CPT) billing codes, alle…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Cytospire secures $83 million to develop pan-gamma delta T-cell engagers
    Cytospire, a British biotechnology startup, announced it raised £61 million, about $83 million, to fund the development of a new type of T-cell engager therapy. The company is targeting a "pan-gam…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • STAT+ examines AI diagnostic claims, telehealth abortion access and Epic lawsuit in latest health tech newsletter
    STAT+ published a health‑tech newsletter that asks whether artificial intelligence has truly outperformed physicians in diagnosing disease, citing a high‑profile study on AI diagnostic performance.…
    STAT · 6mo agoNeutral↗ source
  • RFK Jr. proposes steps to curb SSRI prescriptions; J&J pushes IBD drug; French regulators fine Novo, Lilly over weight-loss ads
    U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced a set of initiatives aimed at reducing the prescribing of selective serotonin reuptake inhibitors, the most widely used clas…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight
    A top Republican is asking if the AMA's codes are helping to fuel health care fraud.
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Supreme Court temporarily restores broad access to abortion pill mifepristone
    The Supreme Court issued an order on Monday that temporarily reinstates wide availability of the abortion medication mifepristone. The order follows a federal appeals court decision that had threat…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Returning doctors face unexpected hurdles and new chances to improve care in their home countries
    The opinion piece argues that the common "brain drain" story about health workers leaving low‑income nations overlooks what happens when they come back. The author cites a breast surgeon who train…
    STAT · 6mo agoNeutral↗ source
  • China's new supply chain rules threaten Western pharma as Beijing tightens control over biotech imports
    China has rapidly expanded its role in drug development, moving from less than 8% of global clinical trials in 2010 to overtaking the United States in trial volume by 2020, with more than 5,000 tri…
    STAT · 6mo agoRegulatoryNegative↗ source
  • French regulator fines Novo Nordisk and Eli Lilly for misleading weight loss ads
    French medicines regulator ANSM imposed fines on Novo Nordisk and Eli Lilly for advertising practices linked to their weight loss drugs. Novo Nordisk was fined about $2 million for ads promoting W…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Latus Bio raises $97 million to advance gene therapies for Huntington’s and Batten disease
    Latus Bio announced closing a $97 million Series A round, including a $43 million extension to a prior $54 million raise. Funding was led by 8VC and included eight other investors such as DCVC Bio…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • UCB to buy Candid Therapeutics for up to $2.2 billion, targeting bispecific antibodies for autoimmune disease
    UCB announced a deal to acquire Candid Therapeutics, a startup focused on bispecific antibody drugs, for an upfront payment of $2 billion with up to $200 million in future milestones. The transacti…
    BioPharma Dive · 6mo agoDealPositive↗ source